Both liraglutide and semaglutide have received FDA approval for the treatment of T2DM, obesity, and cardiovascular risk reduction [ Table 2 ]
The approach most providers recommend involves tracking caloric intake during the first several weeks on medication, ensuring a minimum of 1,800 calories daily while breastfeeding (some women need more depending on supply demands and body size), and prioritizing protein and nutrient-dense foods over empty calories
The good news for those considering weight loss treatment is that GLP-1 medications are FSA eligible, allowing you to leverage your pre-tax savings for treatment
Is Your Appetite Really the Problem
This happens either because the pancreas does not produce enough insulin or because the body cannot use insulin effectively
Novo Nordisk offers self-pay pricing through its NovoCare pharmacy, with some doses starting at $149 per month